KOL Mapping for Launch Strategy

Use Case 1: Medical Affairs Use Case 2: Launch Strategy Use Case 3: Market Access Use Case 4: KEE Mapping Use Case 5: Early-Phase
📄 USE CASE 2 OF 5  |  Slug: /kol-mapping-for-launch-strategy/

KOL Mapping for Pharma Launch Strategy: Building the Expert Relationships That Shape Market Reception

Launch StrategyPre-LaunchCommercial PlanningExpert Engagement

👥 Built for: Launch Excellence Teams, Commercial Directors, Brand Teams, and Medical Affairs Launch Leads

The expert relationships your team builds in the 12–24 months before launch determine how your product is received at market entry — and how quickly it builds clinical credibility beyond early adopters. The organisations that consistently achieve strong launches are those that commission rigorous KOL mapping early enough to act on it. Those that commission it at launch, or not at all, are always playing catch-up with competitors who started sooner.

🔸 What Launch Teams Get Wrong About KOL Engagement

  • Relying on established KOL relationships from previous products — without mapping the specific expert landscape for the new therapy area and indication
  • Missing the emerging experts who will shape peer-to-peer conversations at launch — because they haven’t yet appeared on traditional KOL radar
  • Overlooking digital opinion leaders who will dominate the digital clinical conversations that increasingly precede and follow launch events
  • Engaging experts too late — when the first-mover relationship window has already closed and competitors have secured the most strategically important voices
  • Building a KOL plan from an in-house list that reflects the team’s existing relationships rather than the therapy area’s actual expert landscape

✓ What KOL Mapping by VML Delivers for Launch Teams

  • Complete pre-launch expert landscape — established leaders, emerging voices, and digital opinion leaders — before competitors have completed the same exercise
  • Tiered engagement prioritisation — which experts to approach first, when, and in what sequence for maximum launch impact
  • Emerging expert identification 12–18 months before conventional KOL lists show them — maximum first-mover advantage
  • DOL mapping that identifies the digital communities where launch conversations will be shaped — and who leads those communities
  • Influence mapping that reveals the most efficient network entry points for a new therapy’s scientific message

The Pre-Launch KOL Mapping Timeline

24M

24 Months Pre-Launch: Commission Initial Expert Ecosystem Map

Full established leader and emerging expert mapping across all target geographies. Identify the scientific platform authors, advisory board candidates, and rising stars to begin engaging immediately. Influence mapping to understand the network architecture the launch will need to navigate.

18M

18 Months Pre-Launch: DOL and Catalyst Mapping

Commission DOL mapping to identify the digital clinical communities relevant to the indication. Commission catalyst of change mapping to understand what is shifting in the therapy area and who is driving it — ensuring launch positioning is aligned with emerging clinical consensus, not just the current one.

12M

12 Months Pre-Launch: Validate and Prioritise

Commission KOL validation on advisory board shortlists, speaker programme candidates, and publication author lists. Confirm current engagement status of priority experts. Update influence maps with any new network developments observed during the engagement programme.

6M

6 Months Pre-Launch: Refresh and Finalise

Refresh the expert landscape with a targeted update — particularly for emerging experts (whose trajectory may have accelerated) and DOLs (whose digital community dynamics may have shifted). Finalise engagement priority lists for the launch period itself.

●

Launch and Post-Launch: Monitor Sentiment Evolution

Track how expert sentiment is evolving in response to real-world use, post-marketing data, and competitive activity. Identify new emerging voices rising in the wake of launch. Update engagement priorities accordingly.

The competitive reality: If your launch team commissions KOL mapping 6 months before launch, your most capable competitors commissioned theirs 18–24 months before launch. The expert relationships they have built in that window are not available to you on launch day. The first-mover advantage in KOL engagement is real, measurable, and directly tied to the timing of mapping investment.

Frequently Asked Questions

When is too late to commission pre-launch KOL mapping?

The most valuable window is 18–24 months pre-launch. At 12 months, emerging expert engagement is still possible but the first-mover window is narrowing. At 6 months, you are mapping a landscape that competitors have already been engaging for a year or more. At launch, KOL mapping shifts from relationship-building intelligence to monitoring — valuable, but not a substitute for the pre-launch investment.

Can KOL mapping support both medical affairs and commercial launch planning in a single programme?

Yes. KOL Mapping by VML programmes can be scoped to serve both medical affairs (scientific exchange, advisory boards, publication authors) and commercial teams (speaker bureau candidates, congress presence, market shaping experts) — with appropriate compliance controls ensuring each function accesses only the intelligence appropriate to their role. → Discuss a joint medical/commercial launch mapping programme

Start Building Your Launch KOL Strategy Before Your Competitors Do

→ Book a pre-launch KOL mapping conversation with KOL Mapping by VML

Related Pages